Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients

University of Southern Denmark (SDU)

Status: Completed

Conditions: Kidney Transplant; Complications

Treatments: Dietary Supplement: Standardized sodium diet; Drug: Tbl amiloride

Study type: Interventional

Funder types: Other

Identifiers

NCT03036748

ENaC activation

Details and patient eligibility

About

The aim of this study is to determine if amiloride, a diuretic drug, is capable of increasing renal salt excretion, lowering blood pressure and inhibiting uPA in kidney transplant recipients with proteinuria compared to normoalbuminuric transplant patients.

Enrollment: 14 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• One Group of kidney transplant recipients with ACR< 30mg/g
• One Group of kidney transplant recipients with ACR >300mg/g

Exclusion criteria

• Treatment with amiloride, spironolactone, aldosterone- or analogs or tranexamsyre
• Pregnancy
• Clinically relevant organic or systemic disease including malignancy
• eGFR or creatinin-clearance < 30ml/min
• hyperkalemia (s-potassium > 5,0mmol/l)

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

14 participants in 2 patient groups

TX control

Experimental group

Description:

Kidney transplant recipients with urinary albumin/creatinin-ratio \< 30mg/g

Treatment:

Drug: Tbl amiloride

Dietary Supplement: Standardized sodium diet

TX Proteinuria

Experimental group

Description:

Kidney transplant recipients with urinary albumin/creatinin-ratio \> 300mg/g

Treatment:

Drug: Tbl amiloride

Dietary Supplement: Standardized sodium diet